EUVIMEDEUVIMED entdecken
Crossref

Dehydrolithocholic Acid (DHLCA) Ameliorates Diabetic Kidney Disease by Activating TGR5/FXR Signaling and Remodeling the Gut Microbiota

Liam Wilson, Noah Baker, Ava Turner

Pharmaceutical Sciences and Drug Design · 2022

DOI: 10.51847/2rlip6mpou ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Sciences and Drug Design, 2022. Verfasst von Liam Wilson und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic kidney disease (DKD) is one of the primary causes of long-term loss of renal function internationally. In recent years, bile acids (BAs) have emerged as important metabolic signals influencing glucose control and kidney physiology. This project explored how disturbances in BA pathways contribute to DKD advancement. Plasma BA concentrations were quantified in healthy individuals (HC), subjects with type 2 diabetes mellitus (T2DM), and patients diagnosed with DKD using ultra-high-performa

Zitieren

APA

Wilson, L., Baker, N., & Turner, A. (2022). Dehydrolithocholic Acid (DHLCA) Ameliorates Diabetic Kidney Disease by Activating TGR5/FXR Signaling and Remodeling the Gut Microbiota. Pharmaceutical Sciences and Drug Design. https://doi.org/10.51847/2rlip6mpou

Vancouver

Wilson L, Baker N, Turner A. Dehydrolithocholic Acid (DHLCA) Ameliorates Diabetic Kidney Disease by Activating TGR5/FXR Signaling and Remodeling the Gut Microbiota. Pharmaceutical Sciences and Drug Design. 2022. doi:10.51847/2rlip6mpou

BibTeX
@article{Wilson2022,
  author = {Wilson, Liam and Baker, Noah and Turner, Ava},
  title = {Dehydrolithocholic Acid (DHLCA) Ameliorates Diabetic Kidney Disease by Activating TGR5/FXR Signaling and Remodeling the Gut Microbiota},
  journal = {Pharmaceutical Sciences and Drug Design},
  year = {2022},
  doi = {10.51847/2rlip6mpou}
}
Kostenlos starten →